EICHORCondition: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms · Sponsor: Merck Sharp & Dohme LLC
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer. The primary study hypotheses are that the combination of pembrolizumab plus carboplatin/paclitaxel\* followed by continued pembrolizumab and maintenance olaparib is superior to carboplatin/paclitaxel alone with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in participants with programmed death-ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\]≥10) and in all participants, and that the combination of pembrolizumab plus carboplatin/paclitaxel followed by continued pembrolizumab is superior to carboplatin/paclitaxel alone with respect to PFS per RECIST 1.1 in participants with PD-L1 positive tumors (CPS≥10) and in all participants.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (UAB) ( Site 0036) | Birmingham, Alabama, United States | — |
| University of Arizona Cancer Center ( Site 0074) | Tucson, Arizona, United States | — |
| Disney Family Cancer Center ( Site 0042) | Burbank, California, United States | — |
| Kaiser Permanente Oncology Clinical Trial -Oakland ( Site 0077) | Oakland, California, United States | — |
| Kaiser Permanente Oncology Clinical Trials-Roseville ( Site 0084) | Roseville, California, United States | — |
| Kaiser Permanente Oncology Clinical Trials-Sacramento ( Site 0083) | Sacramento, California, United States | — |
| Kaiser Permanente Oncology Clinical Trial - San Francisco ( Site 0078) | San Francisco, California, United States | — |
| Kaiser Permanente Oncology Clinical Trial - Santa Clara ( Site 0079) | Santa Clara, California, United States | — |
| Kaiser Permanente N. CA Regional Oncology Clinical Trials ( Site 0008) | Vallejo, California, United States | — |
| Kaiser Permanente Oncology Clinical Trial - Walnut Creek ( Site 0080) | Walnut Creek, California, United States | — |
| Smilow Cancer Center at Yale-New Haven ( Site 0057) | New Haven, Connecticut, United States | — |
| Sarasota Memorial Hospital ( Site 0023) | Sarasota, Florida, United States | — |
+ 215 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03740165